K Peggs
About
In The Last Decade
K Peggs
12 papers receiving 209 citations
Peers
Comparison fields: 5 of 35
- Pathology and Forensic Medicine 102
- Oncology 88
- Hematology 73
- Neurology 42
- Epidemiology 39
Countries citing papers authored by K Peggs
This map shows the geographic impact of K Peggs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K Peggs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K Peggs more than expected).
Fields of papers citing papers by K Peggs
This network shows the impact of papers produced by K Peggs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K Peggs. The network helps show where K Peggs may publish in the future.
Co-authorship network of co-authors of K Peggs
This figure shows the co-authorship network connecting the top 25 collaborators of K Peggs. A scholar is included among the top collaborators of K Peggs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K Peggs. K Peggs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 3 | |
| 2 | Reduced intensity conditioned allogeneic stem cell transplantation (RIC-Allo) as front-line therapy for mantle cell lymphoma (MCL): Results from the UK Phase II Mini Allo Study (CRUK: C7627/A9080) | 2 |
| 3 | 32 | |
| 4 | REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION FOR MANTLE CELL LYMPHOMA: THE EBMT EXPERIENCE | 1 |
| 5 | 71 | |
| 6 | 7 | |
| 7 | 1 | |
| 8 | Long term results of reduced intensity transplantation in multiply relapsed and refractory Hodgkin's lymphoma: Evidence of a therapeutically relevant graft-versus-lymphoma effect. | 5 |
| 9 | Long-term follow-up of an alemtuzumab (CAMPATH-1H) containing reduced intensity allogeneic transplant regimen for non-Hodgkin's lymphoma (NHL). | 2 |
| 10 | Non-myeloablative transplantation for patients with Hodgkin's disease: Limited transplant related mortality and possible evidence of a graft versus Hodgkin's effect. | 4 |
| 11 | Simultaneous occurrence of Clostridium difficile and Cytomegalovirus colitis in a recipient of autologous stem cell transplantation. | 5 |
| 12 | 78 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.